211 related articles for article (PubMed ID: 36766786)
21. Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p.
Al-Momany B; Hammad H; Ahram M
Curr Mol Pharmacol; 2021; 14(5):860-870. PubMed ID: 34061013
[TBL] [Abstract][Full Text] [Related]
22. Enzalutamide Overcomes Dihydrotestosterone-Induced Chemoresistance in Triple- Negative Breast Cancer Cells
Alsawalha L; Ahram M; Abdullah MS; Dalmizrak O
Anticancer Agents Med Chem; 2022; 22(17):3038-3048. PubMed ID: 35579133
[TBL] [Abstract][Full Text] [Related]
23. Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
Sharifi MN; O'Regan RM; Wisinski KB
Clin Breast Cancer; 2023 Dec; 23(8):813-824. PubMed ID: 37419745
[TBL] [Abstract][Full Text] [Related]
24. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.
Cuenca-López MD; Montero JC; Morales JC; Prat A; Pandiella A; Ocana A
BMC Cancer; 2014 Apr; 14():302. PubMed ID: 24779793
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells.
Browne G; Dragon JA; Hong D; Messier TL; Gordon JA; Farina NH; Boyd JR; VanOudenhove JJ; Perez AW; Zaidi SK; Stein JL; Stein GS; Lian JB
Tumour Biol; 2016 Jul; 37(7):8825-39. PubMed ID: 26749280
[TBL] [Abstract][Full Text] [Related]
26. A novel transcriptional network for the androgen receptor in human epididymis epithelial cells.
Yang R; Browne JA; Eggener SE; Leir SH; Harris A
Mol Hum Reprod; 2018 Sep; 24(9):433-443. PubMed ID: 30016502
[TBL] [Abstract][Full Text] [Related]
27. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
28. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.
Caiazza F; Murray A; Madden SF; Synnott NC; Ryan EJ; O'Donovan N; Crown J; Duffy MJ
Endocr Relat Cancer; 2016 Apr; 23(4):323-34. PubMed ID: 26932782
[TBL] [Abstract][Full Text] [Related]
30. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.
McNamara KM; Yoda T; Nurani AM; Shibahara Y; Miki Y; Wang L; Nakamura Y; Suzuki K; Yang Y; Abe E; Hirakawa H; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Brown KA; Ohuchi N; Sasano H
Breast Cancer Res Treat; 2014 Jun; 145(2):281-93. PubMed ID: 24715382
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
[TBL] [Abstract][Full Text] [Related]
32. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
33. Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling.
Kanai A; McNamara KM; Iwabuchi E; Miki Y; Onodera Y; Guestini F; Khalid F; Sagara Y; Ohi Y; Rai Y; Yamaguchi R; Tanaka M; Miyashita M; Ishida T; Sasano H
Breast Cancer Res Treat; 2020 Feb; 180(1):97-110. PubMed ID: 31989378
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
35. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
[TBL] [Abstract][Full Text] [Related]
36. Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review.
Choupani E; Mahmoudi Gomari M; Zanganeh S; Nasseri S; Haji-Allahverdipoor K; Rostami N; Hernandez Y; Najafi S; Saraygord-Afshari N; Hosseini A
Pharmacol Rev; 2023 Mar; 75(2):309-327. PubMed ID: 36781219
[TBL] [Abstract][Full Text] [Related]
37. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
38. The role of activated androgen receptor in cofilin phospho-regulation depends on the molecular subtype of TNBC cell line and actin assembly dynamics.
Tahtamouni L; Alzghoul A; Alderfer S; Sun J; Ahram M; Prasad A; Bamburg J
PLoS One; 2022; 17(12):e0279746. PubMed ID: 36584207
[TBL] [Abstract][Full Text] [Related]
39. Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer.
Jinna N; Rida P; Smart M; LaBarge M; Jovanovic-Talisman T; Natarajan R; Seewaldt V
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012111
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.
He J; Lee HJ; Saha S; Ruan D; Guo H; Chan CH
Cell Death Dis; 2019 Mar; 10(4):285. PubMed ID: 30918246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]